14 hours ago
1
koto_feja/E+ via Getty Images
- Cardiff Oncology (NASDAQ:CRDF) reported results from a mid-stage trial testing its experimental drug Onvansertib alongside standard treatment for patients with RAS-mutated metastatic colorectal cancer.
- The trial showed that 49% of patients receiving a 30mg dose of Onvansertib had a confirmed overall
English (US) ·